ZA200706740B - Quinazolinone T-type calcium channel antagonists - Google Patents
Quinazolinone T-type calcium channel antagonistsInfo
- Publication number
- ZA200706740B ZA200706740B ZA200706740A ZA200706740A ZA200706740B ZA 200706740 B ZA200706740 B ZA 200706740B ZA 200706740 A ZA200706740 A ZA 200706740A ZA 200706740 A ZA200706740 A ZA 200706740A ZA 200706740 B ZA200706740 B ZA 200706740B
- Authority
- ZA
- South Africa
- Prior art keywords
- type calcium
- quinazolinone
- calcium channel
- channel antagonists
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65995405P | 2005-03-09 | 2005-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200706740B true ZA200706740B (en) | 2008-09-25 |
Family
ID=36992208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200706740A ZA200706740B (en) | 2005-03-09 | 2007-08-14 | Quinazolinone T-type calcium channel antagonists |
Country Status (15)
Country | Link |
---|---|
US (2) | US7745452B2 (xx) |
EP (1) | EP1858520B1 (xx) |
JP (1) | JP2008533020A (xx) |
KR (1) | KR20070110081A (xx) |
CN (1) | CN101137380A (xx) |
AT (1) | ATE527243T1 (xx) |
AU (1) | AU2006223469A1 (xx) |
BR (1) | BRPI0608343A2 (xx) |
CA (1) | CA2600868A1 (xx) |
IL (1) | IL185391A0 (xx) |
MX (1) | MX2007010965A (xx) |
NO (1) | NO20075074L (xx) |
RU (1) | RU2007137266A (xx) |
WO (1) | WO2006098969A2 (xx) |
ZA (1) | ZA200706740B (xx) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7745452B2 (en) * | 2005-03-09 | 2010-06-29 | Merck Sharp & Dohme Corp. | Quinazolinone T-type calcium channel antagonists |
CA2685753A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
CA2692783A1 (en) * | 2007-07-10 | 2009-01-15 | Merck Sharp & Dohme Corp. | Quinazolinone t-type calcium channel antagonists |
US8273749B2 (en) | 2007-10-04 | 2012-09-25 | Merck Sharp & Dohme Corp. | N-substituted oxindoline derivatives as calcium channel blockers |
AU2008308092B2 (en) * | 2007-10-05 | 2013-07-11 | Msd K.K. | Benzoxazinone derivative |
WO2010047674A1 (en) | 2008-10-20 | 2010-04-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Low molecular weight thyroid stimulating hormone receptor (tshr) agonists |
FR2937552B1 (fr) * | 2008-10-27 | 2011-05-06 | Biocodex | Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique |
US9206154B2 (en) | 2010-04-08 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inverse agonists and neutral antagonists for the TSH receptor |
CA2800521A1 (en) | 2010-05-24 | 2011-12-01 | Toa Eiyo Ltd. | Fused imidazole derivative |
WO2014048532A1 (en) * | 2012-09-26 | 2014-04-03 | Merck Patent Gmbh | Quinazolinone derivatives as parp inhibitors |
IN2014CH00304A (xx) * | 2014-01-24 | 2015-09-04 | Discovery Intermediates Pvt Ltd | |
US9145388B2 (en) | 2014-02-19 | 2015-09-29 | King Fahd University Of Petroleum And Minerals | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
JP6500201B2 (ja) | 2014-05-28 | 2019-04-17 | トーアエイヨー株式会社 | 置換トロパン誘導体 |
JP6957460B2 (ja) | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドCavion, Inc. | アンジェルマン症候群および関連する障害の処置方法 |
CA3053781A1 (en) | 2017-02-15 | 2018-08-23 | Cavion, Inc. | Benzopyran and naphalene derivatives and their uses as calium channel inhibitors |
CN106749045B (zh) * | 2017-03-03 | 2020-02-14 | 上海交通大学 | 一种d-氨基酸氧化酶抑制剂及其制法和应用 |
US11324733B2 (en) | 2017-04-26 | 2022-05-10 | Cavion, Inc. | Methods for improving memory and cognition and for treating memory and cognitive disorders |
MX2021003706A (es) | 2018-10-03 | 2021-11-04 | Cavion Inc | Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida. |
BR112022000429A2 (pt) | 2019-07-11 | 2022-03-29 | Praxis Prec Medicines Inc | Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos |
AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102764A0 (en) * | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
WO1993004047A1 (en) * | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
DE4320347A1 (de) * | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
EP1066039A4 (en) * | 1998-03-02 | 2003-02-26 | Cocensys Inc | SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
JP3691341B2 (ja) * | 2000-05-16 | 2005-09-07 | 日新製鋼株式会社 | 精密打抜き性に優れたオーステナイト系ステンレス鋼板 |
AU2003277418A1 (en) * | 2002-10-17 | 2004-05-04 | Merck And Co., Inc. | Enhancement of sleep with t-type calcium channel antagonists |
CN1856310A (zh) * | 2003-09-23 | 2006-11-01 | 默克公司 | 喹唑啉钾通道抑制剂 |
US20070010537A1 (en) * | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
US7745452B2 (en) * | 2005-03-09 | 2010-06-29 | Merck Sharp & Dohme Corp. | Quinazolinone T-type calcium channel antagonists |
CA2573525A1 (en) * | 2006-01-12 | 2007-07-12 | Hitachi, Ltd. | Materials location system and selecting method of materials receiving locations |
-
2006
- 2006-03-08 US US11/886,053 patent/US7745452B2/en active Active
- 2006-03-08 KR KR1020077020586A patent/KR20070110081A/ko not_active Withdrawn
- 2006-03-08 MX MX2007010965A patent/MX2007010965A/es unknown
- 2006-03-08 AT AT06737357T patent/ATE527243T1/de not_active IP Right Cessation
- 2006-03-08 CN CNA2006800072450A patent/CN101137380A/zh active Pending
- 2006-03-08 EP EP06737357A patent/EP1858520B1/en active Active
- 2006-03-08 RU RU2007137266/04A patent/RU2007137266A/ru not_active Application Discontinuation
- 2006-03-08 WO PCT/US2006/008177 patent/WO2006098969A2/en active Application Filing
- 2006-03-08 JP JP2008500859A patent/JP2008533020A/ja not_active Withdrawn
- 2006-03-08 AU AU2006223469A patent/AU2006223469A1/en not_active Abandoned
- 2006-03-08 CA CA002600868A patent/CA2600868A1/en not_active Abandoned
- 2006-03-08 BR BRPI0608343A patent/BRPI0608343A2/pt not_active IP Right Cessation
-
2007
- 2007-08-14 ZA ZA200706740A patent/ZA200706740B/xx unknown
- 2007-08-20 IL IL185391A patent/IL185391A0/en unknown
- 2007-10-08 NO NO20075074A patent/NO20075074L/no not_active Application Discontinuation
-
2010
- 2010-06-28 US US12/824,702 patent/US20100261741A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006223469A1 (en) | 2006-09-21 |
CN101137380A (zh) | 2008-03-05 |
WO2006098969A2 (en) | 2006-09-21 |
EP1858520A2 (en) | 2007-11-28 |
US7745452B2 (en) | 2010-06-29 |
IL185391A0 (en) | 2008-02-09 |
US20100261741A1 (en) | 2010-10-14 |
NO20075074L (no) | 2007-11-30 |
US20080167329A1 (en) | 2008-07-10 |
BRPI0608343A2 (pt) | 2016-10-04 |
EP1858520B1 (en) | 2011-10-05 |
CA2600868A1 (en) | 2006-09-21 |
MX2007010965A (es) | 2007-09-19 |
ATE527243T1 (de) | 2011-10-15 |
JP2008533020A (ja) | 2008-08-21 |
EP1858520A4 (en) | 2010-02-10 |
KR20070110081A (ko) | 2007-11-15 |
RU2007137266A (ru) | 2009-04-20 |
WO2006098969A3 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200706740B (en) | Quinazolinone T-type calcium channel antagonists | |
WO2007120729A3 (en) | Pyridyl amide t-type calcium channel antagonists | |
MX2010004530A (es) | Antagonistas de los canales de calcio tipo t de heterociclo fenil amida. | |
WO2007002884A3 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
WO2007002361A3 (en) | 3-fluoro-piperidine t-type calcium channel antagonists | |
TW200714604A (en) | Substituted heterocycles and the uses thereof | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2008008551A3 (en) | 2-substituted proline bis-amide orexin receptor antagonists | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
DE602007008434D1 (de) | Rezeptoren | |
EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
HK1166983A1 (zh) | 包含用於治療疾病或紊亂的化合物的固體形式,其組合物,及其用途 | |
MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
WO2007126934A3 (en) | Amidoethylthioether orexin receptor antagonists | |
SG151327A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
DE602004013563D1 (de) | Rantagonisten | |
WO2004087649A3 (en) | Benodiazepine spirohydantoin cgrp receptor antagonists | |
MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
MY149492A (en) | Immunoglobulins directed against nogo | |
WO2006058868A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen |